中西医结合治疗晚期非小细胞肺癌队列疗效预测模型的建立(5)
nib in ALK-positive lung cancer[J]. Lancet, 2017,390(189):3-4.[18]HIDA T, NOKIHARA H, KONDO M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial[J]. Lancet ......
您现在查看是摘要页,全文长 2291 字符。